How Long Do Peptides Take to Work?

Peptide therapy timelines depend on which peptide you’re using, how it’s administered, and what you’re trying to achieve. Most people notice initial changes within 21 days — and full benefits typically develop over 3 to 6 months of consistent use. That said, there’s a 30 to 50% variation in individual response, and knowing what to expect at each stage is the most reliable way to avoid quitting too soon.

This guide breaks down the timeline phase by phase, peptide by peptide, and explains the six variables that determine how fast you see results.

Key takeaways

• Most peptides produce noticeable results within 21 days, with full benefits emerging over 3 to 6 months of consistent use
• Healing peptides like BPC-157 show the fastest onset at 7 to 14 days; growth hormone peptides (CJC-1295/Ipamorelin) take 2 to 3 weeks; GLP-1 weight-loss peptides need 4 to 6 weeks
• Subcutaneous injection delivers 85 to 95% bioavailability — the most reliable method for predictable timelines
• Individual response varies 30 to 50% based on age, metabolic health, dosing consistency, and lifestyle factors
• Medical supervision allows protocol adjustments that can prevent premature discontinuation and optimize results

Before you start All peptide protocols require a physician evaluation before use. Dosing frequency, administration method, and treatment duration should be determined by a licensed physician based on your specific health status, goals, and baseline lab work.

Understanding peptide timeline phases

Peptide therapy doesn’t produce results on day one. It follows four predictable phases — and knowing where you are in that cycle makes a significant difference in whether you stay the course or quit prematurely.

Key takeaways

• Phase 1 (days 1–7): cellular uptake — no perceptible changes for most people
• Phase 2 (days 8–21): onset period — first noticeable changes appear
• Phase 3 (weeks 3–12): progressive improvement — objective measurements become detectable
• Phase 4 (months 3–6): full efficacy — maximum therapeutic benefit plateau

Phase 1: cellular uptake (days 1 to 7)

During the first week, the peptide enters your system, binds to target receptors, and begins accumulating in tissues. Most people feel little to nothing during this window. The peptide is working at the cellular level, but measurable or perceptible changes haven’t yet reached threshold.

A few early signals are possible. Sleep quality may improve slightly for people on CJC-1295/Ipamorelin, because growth hormone pulses increase during deep sleep. BPC-157 users with acute injuries may notice mild pain reduction by days 5 to 7. For GLP-1 peptides, the starting dose — typically 0.25 mg semaglutide — is intentionally low to allow your body to adjust, so expect nothing dramatic yet.

Phase 2: onset period (days 8 to 21)

This is when real changes become noticeable. Tissue accumulation reaches a tipping point, and patient-reported improvements become the primary indicator of early response.

• BPC-157 users commonly report reduced pain and improved mobility within 7 to 14 days of consistent subcutaneous dosing at 250 to 500 mcg daily
• CJC-1295/Ipamorelin users typically notice better sleep, faster workout recovery, and subtle energy improvements by weeks 2 to 3
• Semaglutide users experience appetite suppression and reduced cravings within weeks 2 to 4, with measurable weight loss of approximately 2% of body weight in month one (Wilding et al., 2021, New England Journal of Medicine)
• MOTS-c users may begin noticing energy and metabolic changes by weeks 3 to 4

Phase 3: progressive improvement (weeks 3 to 12)

Cumulative peptide effects build during this phase. Objective measurements become detectable — body composition scans, lab panels (IGF-1, inflammatory markers), and clinical assessments capture real change.

CJC-1295/Ipamorelin users typically see measurable improvements in body composition after 4 to 6 weeks of consistent use. BPC-157 users with soft tissue injuries often experience substantial functional improvement by weeks 4 to 6. GLP-1 users see the most visible weight reduction during this window — the STEP 1 trial (Wilding et al., 2021) recorded an average of 9.6% of baseline body weight lost by week 12.

Week 6 is a common checkpoint for protocol adjustment. If onset hasn’t occurred by the expected timeframe, a physician can modify dosing, switch administration routes, or reassess the protocol.

Phase 4: full efficacy (months 3 to 6)

Maximum therapeutic benefit plateaus during this final phase. New protein synthesis patterns, metabolic shifts, or tissue remodeling reach their peak. People on chronic protocols — anti-aging, weight management — transition to maintenance dosing at this stage.

Learn more about the difference between acute and chronic peptide therapy.

Peptide-specific timelines

Timeline varies by therapeutic category. Healing peptides act directly on injured tissue and produce the fastest response. Growth hormone peptides require a hormonal cascade to build up. Metabolic peptides alter systemic processes gradually.

Key takeaways

• BPC-157 has the fastest onset: 7 to 14 days for initial tissue repair effects
• CJC-1295/Ipamorelin reaches onset in 2 to 3 weeks, with full results over 3 to 6 months
• Semaglutide produces appetite changes in weeks 2 to 4, meaningful weight loss by weeks 4 to 6
• FDA regulatory status varies significantly across peptide classes — see the table below

Peptide	Category	Onset	Full efficacy	Typical duration	FDA status (March 2026)
BPC-157	Healing/tissue repair	7–14 days	4–6 weeks	4–8 weeks (acute)	Category 2 (reclassification pending)
CJC-1295 + Ipamorelin	Growth hormone/anti-aging	2–3 weeks	3–6 months	Ongoing	Category 2 (reclassification pending)
Semaglutide (Wegovy)	Weight loss (GLP-1)	2–4 weeks (appetite); 4–6 weeks (weight)	3–6 months	Ongoing (indefinite)	FDA-approved
MOTS-c	Metabolism/mitochondrial	3–4 weeks	8–12 weeks	Ongoing	Category 2 (reclassification pending)
Thymosin Alpha-1	Immune modulation	2–3 weeks	2–3 months	Variable	Category 2 (reclassification pending)
Semax	Cognitive/neuroprotective	1–2 weeks	4–6 weeks	4–8 weeks	Category 2 (reclassification pending)
NAD+	Cellular energy	2–3 weeks	4–8 weeks	Ongoing	Supplement
Glutathione	Antioxidant	3–4 weeks	2–3 months	Ongoing	Supplement

Healing peptides: BPC-157

Body Protection Compound-157 (BPC-157) is a 15-amino acid peptide derived from a protein found in human gastric juice. Preclinical studies consistently show accelerated tendon, ligament, muscle, and bone healing in animal models.

A 2025 systematic review (Vasireddi et al., HSS Journal) analyzed 544 articles spanning 1993 to 2024, finding 35 preclinical studies and 1 clinical study — all showing improved structural and functional outcomes.

Human evidence remains limited. Only three published human studies exist as of early 2026, with fewer than 30 total subjects studied. A 2021 pilot study (Lee & Padgett, Alternative Therapies in Health and Medicine) reported that 7 of 12 patients with chronic knee pain experienced relief lasting over 6 months after intra-articular BPC-157 injection. Onset for those patients occurred within the first 2 weeks of treatment.

PeptideRx rates the evidence for BPC-157 tissue repair timelines as Grade B, reflecting limited human clinical trials with supportive preclinical data and established pharmacokinetic mechanisms.

Learn more about BPC-157’s healing applications and current regulatory status.

Growth hormone peptides: CJC-1295 and Ipamorelin

CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that extends the natural half-life of GHRH. Ipamorelin is a selective growth hormone secretagogue (a compound that stimulates secretion) that triggers short GH pulses without raising cortisol or prolactin. Together, they mimic the body’s natural GH rhythm.

A foundational pharmacokinetic study (Teichman et al., 2006) showed that CJC-1295 has a half-life of 5.8 to 8.1 days and produces sustained IGF-1 elevation for up to 28 days after multiple doses (PMID: 16352683). That cumulative buildup explains why growth hormone peptides need weeks — not days — before you notice results.

Clinically, people typically report improved sleep and recovery within 2 to 3 weeks, with visible changes in muscle tone and body composition appearing at 4 to 6 weeks.

Learn more about how CJC-1295 and Ipamorelin work together.

Weight-loss peptides: GLP-1 agonists

Semaglutide — sold as Wegovy for weight management — is an FDA-approved GLP-1 (glucagon-like peptide-1) receptor agonist. It follows a dose-titration schedule starting at 0.25 mg weekly.

The STEP 1 trial (1,961 adults, Wilding et al., 2021, New England Journal of Medicine) documented an average weight loss of 14.9% from baseline over 68 weeks. Most people report appetite changes within weeks 1 to 4, with meaningful weight loss becoming visible between weeks 4 and 12.

Semaglutide operates through a different regulatory pathway than compounded peptides. GLP-1 agonists are FDA-approved prescription medications — not compounded substances.

Learn more about semaglutide dosing and what to expect in the first 12 weeks.

What affects how quickly peptides work

Six variables determine how fast you see results from peptide therapy. Administration method has the largest impact, followed by baseline health, protocol adherence, diet, exercise, and sleep.

Administration method

Subcutaneous injection (under-skin injection) is the standard delivery route for most therapeutic peptides. It delivers approximately 85 to 95% of the peptide into your bloodstream, producing predictable and consistent timelines.

Oral administration reduces bioavailability to roughly 30 to 50%. Digestive enzymes break down most peptides before absorption, extending onset by approximately 1 to 2 weeks compared to subcutaneous injection. BPC-157 is an exception — it survives the acidic stomach environment, making oral delivery a viable (though slower) option.

Intravenous (IV) administration provides 100% bioavailability and the fastest peak concentration. It requires a clinic visit, making it impractical for daily protocols. A 2025 pilot study (Lee & Burgess, Alternative Therapies in Health and Medicine, PMID: 40131143) tested IV BPC-157 infusions of 10 to 20 mg in 2 healthy adults and found no adverse effects, with plasma levels returning to baseline within 24 hours.

Baseline health status

Individual response to peptide therapy varies by 30 to 50%. Age, metabolic health, hormone levels, and the severity of the condition being addressed all affect onset speed. Younger, healthier people tend to reach onset faster. Those with chronic conditions or metabolic dysfunction may need longer to see measurable results.

Protocol adherence

Missed doses delay onset. Peptides work through cumulative signaling — skipping injections disrupts the buildup of tissue-level concentrations. Consistency with prescribed dosing schedules is the single most controllable factor in timeline predictability.

Diet, exercise, and sleep

Protein intake of approximately 1 gram per pound of bodyweight provides the amino acid building blocks that peptides need to stimulate repair and growth. Resistance training increases blood flow to target tissues and may improve receptor sensitivity. Sleep quality directly affects growth hormone peptide results, because the largest natural GH pulse occurs during slow-wave (deep) sleep. For semaglutide users, pairing appetite suppression with balanced nutrition accelerates fat loss.

Learn more about lifestyle factors that support peptide therapy results.

Administration methods and timeline impact

The route you use to take a peptide directly affects how quickly and reliably it works.

Method	Bioavailability	Onset speed	Patient experience	Timeline consistency	Typical cost
Subcutaneous injection	85–95%	Baseline (standard)	Self-injectable after training	Highly predictable	$30–$200/month
Intravenous (IV)	100%	Immediate peak	Clinic visit required	Variable (appointment-dependent)	$150–$400/session
Oral	30–50%	Delayed 30–50%	Most convenient	Less predictable (GI factors)	$50–$150/month

Learn more about subcutaneous injection technique and what to expect at your first administration.

How half-life determines dosing frequency

A peptide’s half-life — how long it stays active in your body — determines how often you inject. Shorter half-life peptides need daily dosing to maintain stable tissue levels. Longer half-life peptides can be dosed less frequently.

• BPC-157 has a short half-life, with plasma levels returning to baseline within 24 hours (Lee & Burgess, 2025). Protocols typically call for daily subcutaneous injection at 250 to 500 mcg.
• CJC-1295 has an extended half-life of 5.8 to 8.1 days (Teichman et al., 2006). Protocols commonly prescribe 2 to 3 injections per week, often paired with daily Ipamorelin.
• Semaglutide has a half-life of approximately 7 days. It is administered once weekly.

Dosing frequency affects timeline consistency. Daily protocols produce steady-state tissue levels faster than weekly protocols — one reason healing peptides reach onset sooner than metabolic peptides.

Learn more about peptide half-lives and how they influence protocol design.

Your peptide therapy journey

Peptide therapy follows a structured path from initial consultation through maintenance. Medical supervision at each stage improves both safety and timeline efficiency.

Week 0: initial consultation. A licensed physician reviews your medical history, sets specific goals, orders baseline lab work (IGF-1, metabolic panel, inflammatory markers as needed), and selects the protocol matched to your condition. Informed consent covers the investigational nature of many peptides and the distinction between compounded peptides and FDA-approved medications.

Week 1: first administration. Your physician or clinic staff trains you on subcutaneous injection technique (if applicable) and starts the dosing protocol. Mild injection-site irritation or slight nausea (for GLP-1 peptides) may occur.

Weeks 2 to 4: onset monitoring. The first evaluation checkpoint. Your physician assesses early response, manages any side effects, and determines whether the protocol is on track. BPC-157 users should show initial improvement by this point. CJC-1295/Ipamorelin users should notice sleep and recovery changes.

Months 2 to 6: progressive improvement. Regular check-ins — typically every 4 to 6 weeks — include lab work, body composition tracking, and symptom review. Dosage adjustments happen based on objective and subjective response. GLP-1 users undergo dose titration during this phase.

Month 6+: maintenance decisions. For acute therapy (injury healing with BPC-157), this is the discontinuation point. For chronic therapy (anti-aging, weight management), your physician determines the long-term maintenance protocol. Some people cycle peptides (8 to 12 weeks on, 4 weeks off); others maintain continuous low-dose protocols.

Learn more about what to expect at each stage of a supervised peptide protocol.

Acute vs. chronic therapy

“How long until it works” and “how long do I need to take it” are two different questions. Confusing them is one of the most common mistakes people make when starting peptide therapy.

Acute therapy: defined endpoint

Acute therapy addresses a specific injury or condition with a defined healing timeline. Once the goal is achieved, the peptide is discontinued.

BPC-157 for tendon or ligament repair is the clearest example. A typical acute protocol runs 4 to 8 weeks. Onset occurs at 7 to 14 days. Full tissue repair is generally reached at 4 to 6 weeks. After the injury heals, BPC-157 is stopped — and the healing effects persist because the tissue has been physically repaired.

Chronic therapy: ongoing maintenance

Chronic therapy addresses conditions that require sustained intervention. Stopping the peptide means the benefits gradually fade.

• GLP-1 agonists for weight loss require indefinite use to maintain results. The STEP 1 trial extension data showed that participants who stopped semaglutide regained approximately two-thirds of lost weight within 12 months.
• CJC-1295/Ipamorelin for anti-aging maintains elevated growth hormone levels only while the peptide is being used. Benefits like improved sleep, body composition, and recovery return to baseline within 2 to 3 months of stopping.
• MOTS-c for metabolic optimization similarly requires ongoing use for sustained mitochondrial and metabolic benefits.

What happens when you stop

Peptide type	What happens after stopping
Healing peptides (BPC-157)	Tissue repair is structural — stopping does not reverse healing
Growth hormone peptides (CJC-1295/Ipamorelin)	GH levels return to pre-treatment baseline over 2 to 3 months
Weight-loss peptides (semaglutide)	Appetite suppression fades; weight regain typically begins within 3 to 6 months

Discontinuation should always be managed by your prescribing physician, who can design tapering protocols when appropriate.

Learn more about managing peptide discontinuation and what to expect.

Safety, monitoring, and FDA regulation

Key takeaways

• Premature dose escalation before the onset window completes introduces unnecessary risk without speeding results
• Premature discontinuation at week 2 may mean stopping just before onset — growth hormone and metabolic peptides require 2 to 4 weeks before the first noticeable changes appear
• As of March 2026, the FDA has not published the formal updated Category list — reclassification is signaled but not yet official

Two timeline-related safety risks

Two common patient errors relate directly to timeline expectations.

Premature dose escalation. People who don’t see results by week 2 may be tempted to increase their dose without physician guidance. Increasing doses before the onset period completes introduces unnecessary risk without speeding up results.

Premature discontinuation. Stopping a peptide at week 2 because “nothing is happening” may mean quitting just before onset. Both errors are preventable with proper medical supervision and realistic timeline expectations.

FDA regulatory status (March 2026)

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides placed on the FDA’s Category 2 restricted list in late 2023 would be reclassified to Category 1.

What Category 2 means: The FDA identified these peptides as presenting potential safety risks due to limited human safety data, immunogenicity concerns, or manufacturing impurity risks. Category 2 status prohibits licensed compounding pharmacies from preparing these peptides for patients.

What Category 1 means: The peptide may be compounded by licensed 503A and 503B pharmacies while remaining under FDA evaluation. Category 1 does not mean the peptide is FDA-approved. No therapeutic peptide — except FDA-approved GLP-1 drugs like semaglutide — has completed the full clinical trial process required for drug approval.

Current status as of March 2026: The FDA has not published its official updated Category list. The February 27 announcement signaled regulatory intent, but formal reclassification through the Federal Register has not yet occurred. Monitor official FDA channels for updates rather than relying on social media or podcast announcements.

Peptides expected to return to Category 1 include BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, Selank, Semax, KPV, MOTS-c, and GHK-Cu. Approximately 5 peptides — including Melanotan II, GHRP-2, and GHRP-6 — are expected to remain restricted due to stronger safety concerns.

Compounding pharmacy requirements

All compounded peptides require a valid prescription from a licensed physician (MD, DO) or, in some states, a nurse practitioner or physician assistant. Licensed compounding pharmacies must comply with 503A standards for patient-specific prescriptions or 503B standards for larger-scale outsourcing facilities. Both operate under USP 795/797 quality and sterility standards.

When to contact your physician

Contact your prescribing physician if you experience any of the following during peptide therapy:

• No onset by the expected timeframe (for example, no improvement from BPC-157 after 3 weeks, or no appetite change from semaglutide after 4 weeks)
• Persistent nausea, injection-site reactions that worsen, headaches, or unusual swelling
• New symptoms unrelated to the peptide’s expected effects

Learn more about monitoring timelines and what your physician will assess at each checkpoint.

The bottom line

Most peptides produce initial results within 21 days — and full benefits over 3 to 6 months. The specific timeline depends on your peptide type, your administration method, and your individual health status. Healing peptides are fastest (7 to 14 days); metabolic peptides are slowest (4 to 6 weeks). Subcutaneous injection delivers the most reliable timeline.

The most important thing to understand is that peptides work through cumulative cellular signaling, not instant effects. Consistent dosing, realistic expectations, and medical supervision produce the best outcomes. If results aren’t appearing in the expected window, that’s a signal to adjust the protocol — not to abandon it.

Talk with a licensed physician before starting any peptide protocol. They can set realistic timelines for your specific situation and adjust the approach if your response falls outside the population average.

Frequently asked questions

How long before I see results from BPC-157?

Initial tissue repair improvements appear within 7 to 14 days. BPC-157 shows the fastest onset among therapeutic peptides. Full healing for soft tissue injuries typically takes 4 to 6 weeks of consistent subcutaneous dosing at 250 to 500 mcg daily.

Do GLP-1 peptides take longer to work than other types?

Yes. GLP-1 agonists like semaglutide show onset at 2 to 4 weeks for appetite changes and 4 to 6 weeks for measurable weight loss. Growth hormone peptides reach onset in 2 to 3 weeks; healing peptides like BPC-157 reach onset in 7 to 14 days. The difference reflects mechanism — semaglutide gradually alters satiety signaling and eating patterns, while BPC-157 acts directly on injured tissue.

Why do some peptides work faster than others?

Timeline differences reflect how each peptide signals your cells. Tissue repair peptides (BPC-157) act directly on injury sites, producing faster visible changes. Growth hormone peptides (CJC-1295/Ipamorelin) require hormonal cascade accumulation over 2 to 3 weeks. Metabolic peptides (semaglutide, MOTS-c) alter systemic processes gradually over 4 to 6 weeks.

Can I speed up peptide results with diet and exercise?

Moderately, yes. Resistance training increases blood flow to target tissues and may improve receptor sensitivity. Adequate protein intake (approximately 1 gram per pound of bodyweight) supports the repair processes peptides stimulate. Sleep quality directly affects growth hormone peptide effectiveness. These optimizations may accelerate onset by 1 to 2 weeks, but they can’t override the fundamental timeline each peptide requires.

How long do I have to take peptides?

That depends on your goal. Acute therapy — BPC-157 for injury healing — runs 4 to 8 weeks total, then stops. Chronic therapy — semaglutide for weight loss, CJC-1295/Ipamorelin for anti-aging — requires ongoing use to maintain benefits. Your prescribing physician determines appropriate duration based on your response and goals.

What happens if I stop peptide therapy?

Effects vary by peptide type. Tissue repair from healing peptides persists after treatment ends. Growth hormone peptide benefits return to baseline over 2 to 3 months. Weight regain after stopping semaglutide typically begins within 3 to 6 months. Always discontinue under physician guidance.

How often do I need to inject peptides?

Injection frequency follows half-life. BPC-157 requires daily dosing, with plasma clearance within 24 hours (Lee & Burgess, 2025). CJC-1295 can be dosed 2 to 3 times weekly, with a half-life of 5.8 to 8.1 days (Teichman et al., 2006). Semaglutide is dosed once weekly, with a half-life of approximately 7 days.

When should I follow up with my doctor during peptide therapy?

Standard monitoring checkpoints are week 3 (onset assessment), week 6 (protocol adjustment if needed), month 3 (full response evaluation with lab work), and month 6+ (maintenance decisions). Schedule an earlier appointment if you experience unexpected side effects or no improvement by the expected onset window.

Are injectable peptides faster than oral?

Yes. Subcutaneous injection provides 85 to 95% bioavailability with predictable timelines. Oral administration delivers only 30 to 50% bioavailability due to digestive enzyme breakdown, extending onset by approximately 30 to 50% — for example, a 2-week subcutaneous onset becomes 3 to 4 weeks orally.

Is the 21-day timeline the same for everyone?

No. Individual response varies 30 to 50% based on age, baseline metabolic health, hormone levels, protocol adherence, and lifestyle factors. Twenty-one days is the population-level average for onset. Medical supervision allows your physician to adjust the protocol if your response falls outside the expected range.

Considering peptide therapy? Consult a licensed physician who can evaluate your health status, review your goals, and determine whether any protocol is appropriate for your situation.

References

1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Bhatt RS. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683
2. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. doi: 10.1177/15563316251355551. PMID: 40756949
3. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med.2021;27. PMID: 36006598
4. Lee E, Burgess K. Safety of intravenous infusion of BPC-157 in humans: a pilot study. Altern Ther Health Med.2025;31(5):20-24. PMID: 40131143
5. Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024;30:12-17
6. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002
7. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: pleiotropic beneficial activity and its possible relations with neurotransmitter activity. Pharmaceuticals (Basel). 2024;17(4):461. PMC: 11053547
8. FDA. Certain bulk drug substances for use in compounding may present significant safety risks. FDA.gov. Updated 2024

Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. No peptide discussed on this page is FDA-approved for the therapeutic uses described, with the exception of FDA-approved GLP-1 receptor agonists (semaglutide, tirzepatide). All other peptides referenced are available only through licensed compounding pharmacies under physician prescription and remain under FDA regulatory evaluation. Dosing ranges cited reflect published clinical protocols and preclinical research; they are not prescribing recommendations.

Always consult a licensed physician before starting any peptide therapy. PeptideRx does not sell peptides or provide medical consultations. Content is reviewed by a licensed medical professional. For the most current FDA regulatory status of any peptide, visit FDA.gov.

PeptideRx rates the evidence for general peptide therapy timelines as Grade B, reflecting limited human clinical trials with supportive preclinical data and established pharmacokinetic mechanisms.